Table 4.
Clinicopathological characteristics and survival data of NSCLC patients studied by immunohistochemistry.
Clinicopathological characteristics | Total cases n (%) |
---|---|
Total | 96 (100) |
Age (years) Median (range) | 67 (44–84) |
Gender | |
Total | 96 (100) |
Male | 90 (93.8) |
Female | 6 (6.2) |
Smoking (pack-years) | |
Total | 96 (100) |
Cases (%) | 39 (40.6) |
Mean (range) | 90.92 (20–165) |
NA | 57 (59.4) |
Primary location | |
Total | 96 (100) |
Left lung | 38 (39.6) |
Right lung | 58 (60.4) |
NA | – |
Histology | |
Total | 96 (100) |
Squamous | 56 (58.3) |
Adenocarcinoma | 32 (33.3) |
Large carcinoma | 8 (8.3) |
NA | – |
Stage | |
Total | 96 (100) |
I | 33 (34.4) |
II | 31 (32.3) |
III | 30 (31.3) |
IV | 2 (2.1) |
NA | – |
Grade | |
Total | 96 (100) |
I | 4 (4.2) |
II | 42 (43.8) |
III | 42 (43.8) |
NA | 8 (8.3) |
Maximum diameter (cm) | |
Total | 96 (100) |
Cases (%) | 94 (98.0) |
Mean (range) | 5.34 (1.10–21.00) |
NA | 2 (2.0) |
Lymph node infiltration | |
Total | 96 (100) |
No | 49 (51.0) |
Yes | 43 (45.8) |
NA | 3 (3.1) |
Metastasis (adrenals) | |
Total | 96 (100) |
No | 17 (17.7) |
Yes | 1 (1.0) |
NA | 78 (81.3) |
Metastasis (liver) | |
Total | 96 (100) |
No | 17 (17.7) |
Yes | 3 (3.1) |
NA | 76 (79.2) |
Metastasis (brain) | |
Total | 96 (100) |
No | 17 (17.7) |
Yes | 6 (6.3) |
NA | 73 (76.0) |
Metastasis (bones) | |
Total | 96 (100) |
No | 13 (13.5) |
Yes | 11 (11.5) |
NA | 72 (75.0) |
Metastasis (adrenals–liver–brain–bones) | |
Total | 96 (100) |
No | 6 (6.3) |
Yes | 21 (21.9) |
NA | 69 (71.9) |
Survival (2 years) | |
Total | 96 (100) |
Dead | 37 (38.5) |
Alive | 57 (59.4) |
NA | 2 (2.1) |
Survival (3 years) | |
Total | 96 (100) |
Dead | 50 (52.1) |
Alive | 42 (43.8) |
NA | 4 (4.2) |
Survival (5 years) | |
Total | 96 (100) |
Dead | 59 (61.5) |
Alive | 33 (34.4) |
NA | 4 (4.2) |
Relapse | |
Total | 96 (100) |
No | 8 (8.3) |
Yes | 14 (14.6) |
NA | 74 (77.1) |
NA, data not available or unknown.